Cargando…

Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients

A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on...

Descripción completa

Detalles Bibliográficos
Autores principales: Clémenceau, Béatrice, Le Bourgeois, Amandine, Guillaume, Thierry, Coste-Burel, Marianne, Peterlin, Pierre, Garnier, Alice, Jullien, Maxime, Ollier, Jocelyn, Grain, Audrey, Béné, Marie C., Chevallier, Patrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563037/
https://www.ncbi.nlm.nih.gov/pubmed/36230971
http://dx.doi.org/10.3390/cells11193010
_version_ 1784808312022237184
author Clémenceau, Béatrice
Le Bourgeois, Amandine
Guillaume, Thierry
Coste-Burel, Marianne
Peterlin, Pierre
Garnier, Alice
Jullien, Maxime
Ollier, Jocelyn
Grain, Audrey
Béné, Marie C.
Chevallier, Patrice
author_facet Clémenceau, Béatrice
Le Bourgeois, Amandine
Guillaume, Thierry
Coste-Burel, Marianne
Peterlin, Pierre
Garnier, Alice
Jullien, Maxime
Ollier, Jocelyn
Grain, Audrey
Béné, Marie C.
Chevallier, Patrice
author_sort Clémenceau, Béatrice
collection PubMed
description A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on cellular specific immunity. Here, both B- (antibodies) and T-cell responses were explored after one (V3 n = 40) or two (V4 n = 12) BNT162b2 mRNA vaccine boosters in 52 allo-HSCT recipients at a median of 755 days post-transplant (<1 year n = 9). Results were compared with those of 12 controls who had received only one booster (BNT162b2 n = 6; mRNA-1273 n = 6). All controls developed protective antibody levels (>250 BAU/mL) and anti-spike T-cell responses. Similarly, 81% of the patients developed protective antibody levels, without difference between V3 and V4 (82.5% vs. 75%, p = 0.63), and 85% displayed T-cell responses. The median frequency of anti-spike T cells did not differ either between controls or the whole cohort of patients, although it was significantly lower for V3 (but not V4) patients. COVID-19 infections were solely observed in individuals having received only one booster. These results indicate that four vaccine injections help to achieve a satisfactory level of both humoral and cellular immune protection in allo-HSCT patients.
format Online
Article
Text
id pubmed-9563037
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95630372022-10-15 Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients Clémenceau, Béatrice Le Bourgeois, Amandine Guillaume, Thierry Coste-Burel, Marianne Peterlin, Pierre Garnier, Alice Jullien, Maxime Ollier, Jocelyn Grain, Audrey Béné, Marie C. Chevallier, Patrice Cells Article A full exploration of immune responses is deserved after anti-SARS-CoV-2 vaccination and boosters, especially in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although several reports indicate successful humoral responses in such patients, the literature is scarce on cellular specific immunity. Here, both B- (antibodies) and T-cell responses were explored after one (V3 n = 40) or two (V4 n = 12) BNT162b2 mRNA vaccine boosters in 52 allo-HSCT recipients at a median of 755 days post-transplant (<1 year n = 9). Results were compared with those of 12 controls who had received only one booster (BNT162b2 n = 6; mRNA-1273 n = 6). All controls developed protective antibody levels (>250 BAU/mL) and anti-spike T-cell responses. Similarly, 81% of the patients developed protective antibody levels, without difference between V3 and V4 (82.5% vs. 75%, p = 0.63), and 85% displayed T-cell responses. The median frequency of anti-spike T cells did not differ either between controls or the whole cohort of patients, although it was significantly lower for V3 (but not V4) patients. COVID-19 infections were solely observed in individuals having received only one booster. These results indicate that four vaccine injections help to achieve a satisfactory level of both humoral and cellular immune protection in allo-HSCT patients. MDPI 2022-09-27 /pmc/articles/PMC9563037/ /pubmed/36230971 http://dx.doi.org/10.3390/cells11193010 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Clémenceau, Béatrice
Le Bourgeois, Amandine
Guillaume, Thierry
Coste-Burel, Marianne
Peterlin, Pierre
Garnier, Alice
Jullien, Maxime
Ollier, Jocelyn
Grain, Audrey
Béné, Marie C.
Chevallier, Patrice
Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
title Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
title_full Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
title_fullStr Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
title_full_unstemmed Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
title_short Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
title_sort strong sars-cov-2 t-cell responses after one or two covid-19 vaccine boosters in allogeneic hematopoietic stem cell recipients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563037/
https://www.ncbi.nlm.nih.gov/pubmed/36230971
http://dx.doi.org/10.3390/cells11193010
work_keys_str_mv AT clemenceaubeatrice strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients
AT lebourgeoisamandine strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients
AT guillaumethierry strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients
AT costeburelmarianne strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients
AT peterlinpierre strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients
AT garnieralice strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients
AT jullienmaxime strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients
AT ollierjocelyn strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients
AT grainaudrey strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients
AT benemariec strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients
AT chevallierpatrice strongsarscov2tcellresponsesafteroneortwocovid19vaccineboostersinallogeneichematopoieticstemcellrecipients